Fred S Apple1, Peter A Simpson, Maryann M Murakami. 1. Hennepin County Medical Center and the University of Minnesota, Department of Laboratory Medicine and Pathology, Minneapolis, MN, USA. apple004@umn.edu
Abstract
OBJECTIVES: This study determined the serum 99th percentile reference value for cTnI measured using the high sensitivity Erenna cTnI assay. DESIGN AND METHODS: Serum was obtained from healthy adults (n=348); aged 18-76 years of which 147 were males and 201 were females. Nonparametric analysis was performed to determine the 99th percentiles. RESULTS: For all subjects, the 99th percentile was 10.19 ng/L; mean concentration=1.45 ng/L, range=0.2 to 34.56 ng/L. By gender, the male and female 99th percentile values were as follows: male=16.58 ng/L, mean concentration=1.72 ng/L, and female=9.36 ng/L, mean concentration=1.25 ng/L, respectively (p=0.108). CONCLUSION: cTnI measured by the high-sensitivity Erenna cTnI assay measured 100% of normal subjects, allowing prospective diagnostic and risk assessment studies to be performed, which are essential for the early detection of cardiac disease and for the management of patients presenting with symptoms suggestive of acute coronary syndrome. 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: This study determined the serum 99th percentile reference value for cTnI measured using the high sensitivity Erenna cTnI assay. DESIGN AND METHODS: Serum was obtained from healthy adults (n=348); aged 18-76 years of which 147 were males and 201 were females. Nonparametric analysis was performed to determine the 99th percentiles. RESULTS: For all subjects, the 99th percentile was 10.19 ng/L; mean concentration=1.45 ng/L, range=0.2 to 34.56 ng/L. By gender, the male and female 99th percentile values were as follows: male=16.58 ng/L, mean concentration=1.72 ng/L, and female=9.36 ng/L, mean concentration=1.25 ng/L, respectively (p=0.108). CONCLUSION:cTnI measured by the high-sensitivity Erenna cTnI assay measured 100% of normal subjects, allowing prospective diagnostic and risk assessment studies to be performed, which are essential for the early detection of cardiac disease and for the management of patients presenting with symptoms suggestive of acute coronary syndrome. 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White Journal: Nat Rev Cardiol Date: 2012-08-25 Impact factor: 32.419
Authors: Thomas J Wang; Kai C Wollert; Martin G Larson; Erin Coglianese; Elizabeth L McCabe; Susan Cheng; Jennifer E Ho; Michael G Fradley; Anahita Ghorbani; Vanessa Xanthakis; Tibor Kempf; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan; James L Januzzi Journal: Circulation Date: 2012-08-20 Impact factor: 29.690
Authors: Nicholas A Marston; Marc P Bonaca; Petr Jarolim; Erica L Goodrich; Deepak L Bhatt; Philippe G Steg; Marc Cohen; Robert F Storey; Per Johanson; Stephen D Wiviott; Eugene Braunwald; Marc S Sabatine; David A Morrow Journal: JAMA Cardiol Date: 2020-11-01 Impact factor: 14.676
Authors: M Odette Gore; Stephen L Seliger; Christopher R Defilippi; Vijay Nambi; Robert H Christenson; Ibrahim A Hashim; Ron C Hoogeveen; Colby R Ayers; Wensheng Sun; Darren K McGuire; Christie M Ballantyne; James A de Lemos Journal: J Am Coll Cardiol Date: 2014-02-12 Impact factor: 24.094
Authors: Nicholas L Mills; Kuan Ken Lee; David A McAllister; Antonia M D Churchhouse; Margaret MacLeod; Mary Stoddart; Simon Walker; Martin A Denvir; Keith A A Fox; David E Newby Journal: BMJ Date: 2012-03-15
Authors: W Frank Peacock; Deborah Diercks; Robert Birkhahn; Adam J Singer; Judd E Hollander; Richard Nowak; Basmah Safdar; Chadwick D Miller; Mary Peberdy; Francis Counselman; Abhinav Chandra; Joshua Kosowsky; James Neuenschwander; Jon Schrock; Elizabeth Lee-Lewandrowski; William Arnold; John Nagurney Journal: Ann Lab Med Date: 2016-09 Impact factor: 3.464